Latest News
6-18-2021
Congratulations to Chung-Yao Hsu for passing his qualifying exam.
4-9-2021
Our group's research on adopting gelated dendritic cells for enhancing anticancer immunotherapy is accepted for publication by Advanced Materials.
3-11-2021
Our group's review article on antiviral nanomedicine for pandemic control is accepted for publication by Drug Delivery and Translational Research.
3-5-2021
Our group's collaborative work with NTUH on a nanoparticle Trm vaccine for universal influenza vaccination is accepted for publication in Molecular Therapy - Methods and Clinical Development.
10-03-2020
Our group's collaborative work with NTU on antiviral nanoparticle vaccine technology received the National Innovation Award (國家新創獎）. Congratulations!
10-03-2020
Dr. Hu received the prestigious Chen-Yuan Lee Young Investigator Award (李鎮源教授醫學研究青年學者獎).
09-03-2020
Sherry received the Best Poster Award at the TIGP-MMP retreat for her work on nanoparticle-based universal influenza vaccine. Congratulations Sherry!
04-30-2020
Saborni passed her thesis defense. Congratulations Dr. Chattopadhyay!
03-12-2020
Saborni's paper on STING agonist nanoshell-mediated synthetic immunogenic cell death for anticancer chemo-immunotherapy is accepted for publication in Nano Letters. Congratulations! [Link]
03-02-2020
Dr. Hu's perspective article on COVID-19 vaccine development is featured in Scientific American. [Link]
11-19-2019
Dr. Hu is named a Highly Cited Researcher for 2019 by the Web of Science Group.
Che-Ming Jack Hu (胡哲銘）
Associate Research Fellow
Institute of Biomedical Sciences, Academia Sinica
Dr. Jack Hu recevied his Ph.D. in Biomedical Engineering from the University of California, San Diego in 2011 and recevied postdoctoral trainings in the Nanoengineering Department of UCSD. He holds a B.S. degree in Biomedical Engineering with minors in Mechanical Engineering and Electrical Engineering from UC Berkeley.
Research Focus
Nanotechnology in medicine has shown tremendous value in drug delivery and vaccine preparations, where pharmacokinetics and immune activation can be finely tuned via rational nanomaterials engineering. The research focus of the laboratory is to develop novel therapeutic nanomaterials with an emphasis toward clinical translation. We seek to adopt an engineering approach to improve treatments for major diseases including cardiovascular disease, cancer, and infectious disease.